Azerium Azacitidine Injection 100 Mg

Back to Medicines
Azerium Azacitidine Injection 100 Mg, image 1

Quality Assurance & Dispatch

WHO-GMP Standard
Cold Chain Logistics
Hospital Procurement
Pan-India Supply
OncologyOncologyN/AIn StockRx Prescription Only

Azerium Azacitidine Injection 100 Mg

Brand: AzeriumSKU: ONC79
Maximum Retail Price (MRP)
₹736(Inclusive of all taxes)
Bulk Hospital Pricing on Enquiry

Product Summary

Azerium Azacitidine Injection 100 mg is a prescription anticancer medicine containing a stated 100 mg of Azacitidine per vial.

Dosage FormN/A
Therapy AreaN/A
PackagingN/A
CategoryOncology
Quantity:
1
Proceed to Checkout

Azerium Azacitidine Injection 100 mg is a prescription oncology medicine identified as containing Azacitidine 100 mg per vial.

Azacitidine is a cytidine nucleoside analogue classified as a hypomethylating agent.

It inhibits DNA methyltransferase activity after incorporation into nucleic acids, leading to reduced DNA methylation and other effects on abnormal cells.

Azacitidine is used in selected treatment settings for myelodysplastic syndromes (MDS), acute myeloid leukemia (AML) and certain related myeloid disorders, depending on applicable approvals and treatment protocols.

IMPORTANT SAFETY WARNINGAzacitidine can cause severe myelosuppression, serious infections, bleeding, kidney toxicity and embryo-fetal harm.

The stated 100 mg vial strength does not establish the prescribed patient dose. Dosing depends on the indication, body surface area, blood counts, kidney function and treatment protocol.

The exact formulation, concentration, vial volume, reconstitution requirements, manufacturer, pack size, storage conditions and approved indications of Azerium must be verified from its approved Indian product documentation.

Marketed by Essentials Emporium Enterprises, Azerium is listed within the oncology pharmaceutical category for hospitals, cancer treatment centres and authorized pharmaceutical buyers.

Key Product Features

Brand NameAzerium
Generic NameAzacitidine
Stated Strength100 mg
Dosage FormInjection
Therapeutic CategoryOncology
Drug ClassHypomethylating Agent
Treatment TypeAntineoplastic Therapy
MechanismDNA Methyltransferase Inhibition and Nucleic Acid Incorporation
Reference UsesSelected MDS, AML and Related Myeloid Disorder Settings
Administration RouteSubcutaneous or Intravenous, as permitted by the approved formulation
Prescription StatusPrescription-only
Major Safety ConcernsMyelosuppression, Infection, Bleeding, Kidney Toxicity and Embryo-Fetal Harm
MonitoringComplete Blood Counts, Kidney Function, Liver Function and Treatment Response